SLXN (Silexion Therapeutics) Total Equity: $0.04 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLXN Silexion Therapeutics Corp SLXN
13 GF Score
Price $0.38
! 1 Warning Sign
View Full Analysis

What is Silexion Therapeutics Total Equity?

Silexion Therapeutics SLXN +1.76% 13 Total Equity is $0.04 Mil as of Jun. 2026. GuruFocus rates SLXN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Silexion Therapeutics's total equity for the quarter that ended in Jun. 2026 was $0.04 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Silexion Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Silexion Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silexion Therapeutics Total Equity Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Equity
-7.08 -12.06 -3.99 2.60

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 6.98 2.60 0.29 0.04
SLXN
13GF Score
Silexion Therapeutics Corp SLXN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silexion Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Silexion Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7.215-4.612
=2.60

Silexion Therapeutics's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=4.246-4.202
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $0.04 Mil mean?
Silexion Therapeutics (SLXN) has a Total Equity of $0.04 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Silexion Therapeutics and its competitors.
Is Silexion Therapeutics' Total Equity too high?
Silexion Therapeutics' current Total Equity is $0.04 Mil. Overall, Silexion Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Silexion Therapeutics' Total Equity compare to DCOY and VRAX?
Silexion Therapeutics' Total Equity of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Silexion Therapeutics and its competitors. Silexion Therapeutics's current Total Equity is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silexion Therapeutics stock overvalued right now?
Silexion Therapeutics (SLXN) has a current Total Equity of $0.04 Mil. The current Total Equity is $0.04 Mil. Silexion Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Silexion Therapeutics (SLXN), the current Total Equity is $0.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Silexion Therapeutics Business Description

Address 12 Abba Hillel Road, Ramat-Gan, ISR, 5250606
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
13GF Score

Get the complete analysis for SLXN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price